GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (STU:82P) » Definitions » Cyclically Adjusted Revenue per Share

Pacira BioSciences (STU:82P) Cyclically Adjusted Revenue per Share : €10.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pacira BioSciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pacira BioSciences's adjusted revenue per share for the three months ended in Mar. 2024 was €2.946. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €10.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Revenue Growth Rate was 11.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pacira BioSciences was 19.90% per year. The lowest was -3.50% per year. And the median was 7.20% per year.

As of today (2024-06-09), Pacira BioSciences's current stock price is €26.20. Pacira BioSciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €10.00. Pacira BioSciences's Cyclically Adjusted PS Ratio of today is 2.62.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pacira BioSciences was 12.28. The lowest was 2.35. And the median was 5.49.


Pacira BioSciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Pacira BioSciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences Cyclically Adjusted Revenue per Share Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.67 4.96 6.92 8.85 9.52

Pacira BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.07 9.21 9.96 9.52 10.00

Competitive Comparison of Pacira BioSciences's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PS Ratio falls into.



Pacira BioSciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.946/131.7762*131.7762
=2.946

Current CPI (Mar. 2024) = 131.7762.

Pacira BioSciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.979 100.560 1.283
201409 1.124 100.428 1.475
201412 1.389 99.070 1.848
201503 1.290 99.621 1.706
201506 1.272 100.684 1.665
201509 1.351 100.392 1.773
201512 1.554 99.792 2.052
201603 1.588 100.470 2.083
201606 1.667 101.688 2.160
201609 1.632 101.861 2.111
201612 1.846 101.863 2.388
201703 1.705 102.862 2.184
201706 1.572 103.349 2.004
201709 1.396 104.136 1.767
201712 1.646 104.011 2.085
201803 1.486 105.290 1.860
201806 1.727 106.317 2.141
201809 1.744 106.507 2.158
201812 2.032 105.998 2.526
201903 1.960 107.251 2.408
201906 2.144 108.070 2.614
201909 2.282 108.329 2.776
201912 2.637 108.420 3.205
202003 2.235 108.902 2.704
202006 1.588 108.767 1.924
202009 2.253 109.815 2.704
202012 2.407 109.897 2.886
202103 2.175 111.754 2.565
202106 2.468 114.631 2.837
202109 2.388 115.734 2.719
202112 3.097 117.630 3.469
202203 3.089 121.301 3.356
202206 3.054 125.017 3.219
202209 3.691 125.227 3.884
202212 3.534 125.222 3.719
202303 3.259 127.348 3.372
202306 3.005 128.729 3.076
202309 2.950 129.860 2.994
202312 2.413 129.419 2.457
202403 2.946 131.776 2.946

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Pacira BioSciences  (STU:82P) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=26.20/10
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pacira BioSciences was 12.28. The lowest was 2.35. And the median was 5.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pacira BioSciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (STU:82P) Business Description

Industry
Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

Pacira BioSciences (STU:82P) Headlines

No Headlines